You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm also recently validated its instrument-agnostic technology's ability to detect up to 20 targets per qPCR well using high-definition PCR.
Roche Diagnostics CEO Thomas Schinecker said the infrastructure put in place due to the pandemic will allow for more diagnostic testing globally.
The test uses prognostic markers to group women based on their risk of 10-year recurrence of ductal carcinoma in situ.
The MiQLab system can look for 27 different targets, allowing the detection of SARS-CoV-2 as well as the determination of specific variants.
The test uses isothermal nucleic acid amplification to return results in 20 minutes at the point of care, and demonstrated 98 percent agreement with PCR testing.
Roche has invested CHF 600 million ($664 million) in manufacturing to add 90 manufacturing lines and has plans to launch 17 new tests in 2021.
The company has two COVID-19 tests: One, a moderate high-complexity test, received EUA in September, while the other is in clinical trials.
The company has developed an analyzer to run PCR, immunochemistry, and cytometry tests at the same time for a variety of diseases including COVID-19.
The company is also working in parallel on an at-home test that would be over the counter and return results within an hour.
The program uses an informatics system that converts genotype results to "traffic lights" telling clinicians whether a drug is acceptable for a certain patient.
Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.
NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.
Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.
In Science this week: review discusses advances in liquid biopsies, and more.